ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sarilumab

Also written as “Sarilumab”, “REGN88” and “sarilumab SAR153191 (REGN88)”.

Its studies are mostly in Arthritis, Rheumatoid · Polymyalgia Rheumatica · Arthritis, Juvenile · Spondylitis, Ankylosing · Coronavirus Infections, led by 2 companies.

Drug pageSarilumab: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 8, 201827 company-led studies, 3 open or runningNext primary completion: Mar 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only223 open or runningphase 4since Feb 8, 2018Feb 2, 2010Mar 1, 2028phase 2 · NCT02991469
Regeneron Pharmaceuticals50 open or runningphase 3since Mar 15, 2020Nov 10, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2009First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT01011959 · 60 enrolled · United States
  2. Dec 2, 2009Phase 1 study in Arthritis, RheumatoidNCT01026519 · 32 enrolled · Russian Federation
  3. Jan 25, 2010Phase 1 study in Arthritis, RheumatoidNCT01055899 · 15 enrolled · United States
  4. Mar 3, 2014Phase 1 study in Arthritis, RheumatoidNCT02097524 · 105 enrolled · United States
  5. Mar 15, 2020Phase 3 study in COVID-19NCT04315298 · 1,912 enrolled · United States

TargetBeta

IL6R →read by rule
“A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), ”NCIt, by rule
“Interleukin-6 receptor alpha subunit antagonist”ChEMBL 37, by rule

Other programs on IL6R

ProgramCompanyFurthest phaseStudies
tocilizumabruleHoffmann-La Rochephase 4130

Studies

All 5 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04315298COVID-19 · United States3CompletedJul 24, 20201,912
NCT02097524Arthritis, Rheumatoid · United States1CompletedApr 2015105
NCT01055899Arthritis, Rheumatoid · United States1CompletedMar 200915
NCT01026519Arthritis, Rheumatoid · Russian Federation1CompletedMar 200932
NCT01011959Arthritis, Rheumatoid · United States1CompletedAug 200960

How it is read

Names in the registry

  • “Sarilumab”, 14 entries
  • “REGN88”, 5 entries
  • “sarilumab SAR153191 (REGN88)”, 3 entries
  • “Sarilumab SAR153191 (REGN88)”, 2 entries
  • “SAR153191 (REGN88)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.